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Summary It has been reported that the rhogenes, which consist of a ras-related small GTPase protein family, regulate cytoskeletal structures
and have the potential to transform cultured cells. To investigate the biological relevance of the rho genes in pancreatic carcinogenesis, we
examined expressions of the rhoA, B and C genes by polymerase chain reaction after reverse transcription (RT-PCR) in 33 cases of ductal
adenocarcinoma of the pancreas. In addition, mutations of the K-ras, rhoA, B and C genes were studied in the same series of tumour tissues
to correlate with rho gene expressions. The expression levels of the rhoC gene were significantly higher in tumours than in non-malignant
portions (P < 0.001). Metastatic lesions overexpressed the rhoC gene compared with primary tumours (P < 0.05). Carcinoma tissues with
perineural invasion and lymph node metastasis exhibited significantly higher expressions of the rhoC gene than tumours without these
manifestations (P < 0.001 and P < 0.05 respectively). Overexpression of the rhoC gene significantly correlated with poorer prognosis of
patients with pancreatic adenocarcinoma (P < 0.05). In contrast, the expression levels of the rhoA and B genes showed no significant
relationship with clinicopathological findings. Mutation was not found either in the rhoA, B or C gene sequences examined. K-ras gene
mutation, detected in 27 out of 33 (81.8%) cases, did not affect the expression levels in any of the rho genes. These suggest that elevated
expression of the rhoC gene may be involved in the progression of pancreatic carcinoma independent of K-ras gene activation.
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Ductal adenocarcinoma of the pancreas is characterized by an
extremely poor prognosis with an overall 5-year survival rate of
only 3% (Warshaw and Castillo, 1992). There has been progress
in molecular genetic analysis of pancreatic carcinogenesis.
Inactivations of tumour-suppressor genes such as p53 and allelic
loss ofchromosome 18q are reported (Barton et al, 1991; Hohne et
al, 1992; Scarpa et al, 1993; Suwa et al, 1994; Seymour et al,
1995). Point mutation at codon 12 of the K-ras oncogene is
frequently observed and is considered to be a crucial step in
pancreatic carcinogenesis (Almoguera et al, 1988; Smit et al,
1988; Hruban et al, 1993). However, the molecular genetic
changes that contribute to aggressive characteristics of pancreatic
carcinoma still remain to be elucidated.
To date, a number of small GTP-binding proteins have been
identifled and are thought to be involved in signal transduction
pathways that control a diverse set of essential cellular functions
such as cell growth, cell differentiation, cytoskeletal organization,
intracellular vesicle transport and secretion (Hall, 1990). The RAS
family members are critical components of GTP-binding proteins
and mutation at either codon 12, 13 or 61 makes RAS proteins in
their active GTP-bound state, resulting in oncogenic potential
(Boguski and McCormick, 1993). Rho proteins constitute one of
the RAS-related subfamilies and are involved in cytoskeletal orga-
nization and cell motility by coordinated assembly of focal adhe-
sion and stress fibres (Ridley and Hall, 1992). In addition, Rho
proteins are regulators of gene expression by activating the Jun
nuclear kinase and the serum response factor, and are necessary for
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cell cycle progression (for reviews Olson, 1996). The Rho family
consists of at least ten proteins, and three rho isoforms have been
identified in the human genome. They are designated as the rhoA,
rhoB and rhoC genes respectively (Yeramian et al, 1987; Chardin
et al, 1988). Cells transformed by oncogenic RAS reveal changes
in their morphology through cytoskeletal actin structures (Bar-
Sagi and Feramisco, 1986). Malignant transformation of NIH3T3
cells is induced by transfection ofthe Aplysia rho gene, which has
95, 94 and 92% homology to the human rhoA, B and C genes
respectively. Activated RhoB augments focus formation of
NIH3T3 cells transformed by oncogenic Ras (Prendergast et al,
1995). These suggest that Rho proteins may play a role in Ras
signal transduction and cell transformation.
In the present study, we investigated quantitative and qualitative
alterations of rhoA, B and C gene expressions to clarify their
biological relevance to pancreatic carcinogenesis and their rela-
tionship with K-ras gene mutation.
MATERIALS AND METHODS
Patients and tissue preparation
Thirty-three cases of ductal adenocarcinoma of the pancreas were
obtained by surgical resection at Kyoto University Hospital
between 1990 and 1995 under written informed consent. Clinical
staging was determined according to the classification ofthe WHO
(Gibson and Sobin, 1978). In 17 out of 33 cases a non-tumorous
portion of the pancreas was also acquired. In five cases only
metastatic lesions without their corresponding primary pancreatic
tumours were obtained because of incomplete radicality. They
comprised three liver metastatic lesions and two cases ofperitoneal
dissemination. After inappropriate tissues were removed, tissue
specimens of non-malignant lesions were immediately stored at
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Table 1 PCR primers used
Gene Sequence' PCR products (bp)
rhoA Ul CTGGTGATTGTTGGTGATGG 183
U2 GATTCGTTGCCTGAGCAATG 221
D GCGATCATAATCTTCCTGCC
rhoB Ul TGCTGATCGTGTTCAGTAAG 189
U2 ATCCGCAAGAAGCTGGTGGT 241
D AGCACATGAGAATGACGTCG
rhoC Ul TCCTCATCGTCTTCAGCAAG 181
U2 CTGCAATCCGAAAGAAGCTG 239
D GAGGATGACATCAGTGTCCG
K-ras U GGAGAGAGGCCTGCTGAAAA
D CTTGACCTGCTGTGTCGAGA 203
,B2m U ACCCCCACTGAAAAAGATGA
D ATCTTCAAACCTCCATGATG 120
'Ul, upstream primer for RT-PCR; U2, upstream primer for PCR-SSCP and
sequencing; U, upstream primer; D, downstream primer.
-80°C. Tissues of tumours were embedded in OCT tissue
compound (Miles, Elkhart, IN, USA), and cryostat sections were
cut at 5 ,um thickness. The tumour portion was identified under a
microscope after haematoxylin and eosin (H & E) staining.
RNA extraction and RT-PCR
Total RNA oftumour tissues was extracted from sections adjacent
to the H & E-stained sections using Trizol (Life Technologies,
MD, USA) according to the manufacturer's protocol. RNA from a
non-malignant portion of the pancreas surrounding the tumours
was also extracted.
Gene expressions were determined by polymerase chain reac-
tion after reverse transcription (RT-PCR) according to the method
described previously (Arao et al, 1994). The PCR primers for rho
gene amplification are listed in Table 1. As the rho genes have
strong homology with each other and only cDNA sequences are
available we tried several sets of primers. We chose primer sets
that gave only one PCR product in polyacrylamide gel electro-
phoresis with an appropriate internal restriction site and gave no
products from genomic DNA (data not shown). The condition of
PCR was as follows: 30 cycles of denaturation at 94°C for 30 s,
annealing at 58°C for 1 min and extension at 720C for 1 min in a
thermal cycler (Perkin-Elmer Cetus). Gene expression was
presented by the relative yield of the PCR product from target
sequences to that from the 2-microglobulin gene. Mean values
from three independent experiments were taken as results.
PCR-SSCP analysis and direct sequencing
PCR-SSCP analysis was performed to determine gene mutations
according to the method ofOrita et al (1989) with minor modifica-
tions. For the SSCP analysis of the K-ras gene, exon 1 was
focused because all the point mutations were confined in exon 1
(Suwa et al, 1994). In the SSCP analysis of the rhoA, B and C
genes, the fragments including codon 14, which is equivalent to
codon 12 ofthe oncogenic mutation in the K-ras gene (Moscow et
al, 1994) were investigated. The fragments analysed were codons
from 1 to 69 for the rhoA, 4 to 83 for the rhoB and 3 to 81 for the
rhoC genes. In brief, PCR fragments were generated from 10 ng of
A
183 bp -
120 bp -
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C
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Figure 1 Expression of the rhoA, B and C genes by RT-PCR. Each number
corresponds to a case number in Table 2. N, non-tumorous pancreas; T,
pancreatic carcinoma tissue
complementary DNA in a 10-pl mixture containing 1.25 mM
dATP, dTTP, dGTP; 0.125 mM dCTP; 1.5 mm magnesium chlo-
ride; 20 pmol of each primer; 10 mM Tris-HCl (pH 8.8); 50 mM
potassium; 0.45 units Taq polymerase (Gibco BRL); and 0.1 ,ul of
[a-32P]dCTP (3000 Ci mmol-'). PCR was carried out for 35 cycles
(1 min at 94°C, 2 min at 550C and 1 min at 72°C) in a Thermal
cycler (Perkin-Elmer Cetus). An aliquot (2.5 gl) from 10 p1 of
amplified products was diluted with 20 gl of stop solution (0.1%
sodium dodecyl sulphate (SDS), 10 mM EDTA). The mixture was
added to loading solution containing 95% formamide, 20 mm
EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol.
Samples were heat denatured at 950C for 3 min and then were
loaded on 6% polyacrylamide gel containing 5% glycerol.
Electrophoresis was performed at room temperature with a
constant power of 35 W for 3 h with a cooling fan. The exposure
ofautoradiography was carried out overnight.
Direct sequencing of the K-ras gene was performed as
described previously (Suwa et al, 1994) using a Circumvent DNA
Sequencing kit (New England Biolab, ML, USA) according to the
manufacturer's protocol.
Statistical analysis
The results of RT-PCR were statistically analysed using the
Mann-Whitney U-test. Spearman's correlation coefficient was
used to determine a relationship between rhoA, B and C expres-
sions. Post-operative survival was defined as the period from the
first operation for pancreatic carcinoma to the time of death and
was analysed by the log-rank test. Patients who died of post-
operative complications were excluded from the analysis.
RESULTS
Expression of the rhoA, B and C genes in relation to
clinicopathological findings
Representative profiles of RT-PCR products are shown in Figure 1.
The expression of the rho genes, K-ras mutation status and
clinicopathological findings are summarized in Table 2. Ductal
adenocarcinoma ofthe pancreas revealed significantly higher levels
of rhoC expression than did non-tumorous portions (mean ± s.d. =
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Table 2 Expressions of rhoA, B, C genes and mutation of K-ras gene in pancreatic adenocarcinoma
rho gone expression K-ras gene rhogene expression K-ras gene
mutationC mutation
Case Age/Sex Histologya Stageb A B C Case Age/Sex Histology Stage A B C
1 62/M W III 1.30 1.34 0.87 CGT 19 68/F M IV 0.88 0.32 0.32 GTT
2 70/M W III 1.87 2.5 1.89 GTT 20 51/M M IV 1.76 1.14 1.21 WT
3 71/F W 1.57 1.22 0.74 GAT 21 60/M M IV 1.24 0.79 0.53 WT
4 54/F W 1.07 0.57 0.58 WT 22 41/F M II 1.27 0.36 0.55 WT
5 66/M W III 1.78 1.13 1.10 GAT 23 60/F M IV 0.47 0.72 1.02 GAT
6 75/M M III 1.72 0.36 0.81 GTT 24 74/M M III 1.11 0.72 0.64 GTT
7 63/F M IV 1.09 0.50 0.62 CGT 25 71/F M III 1.39 0.72 0.67 GTT
8 63/M M 1.25 0.67 0.49 GTT 26 61/M M IV 0.95 0.19 0.67 GAT
9 73/M M IV 1.72 0.74 1.00 GAT 27 73/M P III 1.17 0.58 0.62 GAT
10 79/M M III 1.15 0.72 0.57 GAT 28 66/M P IV 0.99 0.68 0.26 WT
11 73/F M 1.86 1.44 0.52 GAT 29 72/M Meta IV 0.92 0.62 1.07 GTT
12 55/M M IV 1.05 0.32 0.38 GTT 30 80/M Meta IV 2.21 2.45 0.89 GAT
13 52/M M III 2.32 1.30 1.75 WT 31 72/M Meta IV 1.58 0.83 1.06 GTT
14 55/F M III 1.48 0.23 0.60 GAT 32 69/M Meta IV 1.11 0.36 0.87 GAT
15 63/F M IV 1.1 0.58 0.80 CGT 33 46/F Meta IV 1.48 1.12 1.22 GTT
16 57/M M IV 0.69 0.26 0.60 GAT
17 69/F M III 1.56 1.03 1.25 GAT
18 54/M M III 1.41 0.47 0.99 CGT
aHistology: W, well; M, moderately; P, poorly differentiated tubularadenocarcinoma; Meta, metastatic adenocarcinoma; bstage according to the classification of
WHO; c all the K-ras mutations involved codon 12. WT, wild type.
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Figure 2 Relationship between the expression levels of the rhoC gene in ductal adenocarcinoma of the pancreas and clinicopathological findings.
(A) Expressions in tumour tissues (T) and in non-tumorous portions (N); (B) expressions in primary tumours (P) and in metastatic lesions (M); (C) tumours with
perineural invasion and those without perineural invasion; (D) tumours with lymph node metastasis and without metastasis. *P < 0.001; **P < 0.05
0.82 ±0.36 and0.49 ±0.20respectively) (Figure 2A). There were no between liver metastasis and peritoneal dissemination. The expres-
significant differences in the expression levels of the rhoA or B sion of the rhoC gene in tumours with perineural invasion was
genes between carcinoma tissues and non-malignant portions (data 1.04 ± 0.34 and that in primary tumours with lymph node metastasis
not shown). Metastatic lesions showed significantly higher rhoC exhibited 0.86 ± 0.38. These expression levels were significantly
mRNA levels (1.02 ± 0.14) than primary pancreatic carcinoma higherthan those withoutperineural invasion (0.61 ±0.18) and those
tissues (0.78 ± 0.38, Figure 2B). These levels were not different without metastasis (0.57 ± 0.09) respectively (Figures 2c and 2d).
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Figure 4 Patient survival in relation to rhoC expression. The patients were
divided into two groups by rhoC expression at 0.82, which corresponded
to the mean value in carcinoma tissues.-, rhoC < 0.82 (n = 17);
. rhoC > 0.82 (n = 14). P < 0.05
0 0
r= 0.50, P< 0.0005
0 O
0 ,.
rhoC
1
rhoC
Figure 3 Correlation among the expressions of the rhoA, B and C genes
There were no significant associations between rho gene
expressions and other clinicopathological findings such as tumour
size, location, age or sex (data not shown). Correlations between
rho A, B and C expressions are shown in Figure 3. Gene expres-
sions between rhoA and rhoB showed moderately positive correla-
tion (correlation coefficient r = 0.68; P < 0.0001). Weakly positive
Figure 5 Histology in relation to rhoC expression. In spite of being a well-
differentiated subtype, Case 5, which is one of the high-expression group
(1.10), showed perineural invasion (A). Case 28 is a poorly differentiated
adenocarcinoma in the low-expression group (0.26). Perineural invasion was
not observed (B). H & E staining. A, x 200; B, x 100
correlation was observed between rhoB and rhoC expressions
(r = 0.50; P < 0.005), and between rhoA and rhoC expressions
(r = 0.50; P < 0.005).
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As the mean value of rhoC expression in carcinoma tissues was
0.82, cases were divided into two groups at this level - high
expression and low expression. Patients in the high expression
group revealed significantly poorer prognosis than the patients in
the low expression group (P < 0.05, Fig. 4). Although case 5 was a
well-differentiated adenocarcinoma, it was one ofthe high-expres-
sion group with perineural invasion (Figure Sa) and lymph node
metastasis (data not shown) and revealed poor prognosis (survival
period was 186 days). In contrast, case 28 was a poorly differenti-
ated carcinoma but was one of the low-expression group without
perineural invasion (Figure Sb) and the patient survived for 462
days after surgical resection. No mutation was found in the frag-
ments ofthe rhoA, B or C genes examined either by PCR-SSCP or
by direct sequencing (data not shown).
K-ras gene mutation
Mutation of the K-ras gene was found in 27 out of 33 (81.8%)
pancreatic carcinoma tissues both by PCR-SSCP and by direct
sequencing. There were no mutations in any of the non-tumorous
portions examined. Sequence analysis revealed that all the K-ras
mutations detected were at codon 12. Mutational patterns were
from GGT to GAT in 13, GTT in ten, and CGT in four cases (Table
2). The expression levels of the rhoC gene in tumour tissues with
K-ras mutation were not significantly different from those without
(0.81 ± 0.55 and 0.83 ± 0.32 respectively). The presence of K-ras
gene mutation had no relationship with clinicopathological find-
ings (data not shown).
DISCUSSION
In the present study we examined the expression levels of the
rhoA, B and C genes, and mutation status of the K-ras gene and
the three rho gene isoforms in human ductal adenocarcinoma of
the pancreas. Although the rho genes have been suspected to be
involved in cell transformation, there are few reports about rho
gene expressions in human tumour tissues. Recently, in vitro assay
revealed that activated RhoA protein is necessary for the motility
of keratinocytes induced by hepatocyte growth factor (Takaishi et
al, 1994) and that the invasive activity ofrat MM1 cells across the
mesothelial cell monolayer is inhibited by Clostridium boturinum
exo-enzyme C3 that specifically inactivates Rho proteins
(Imamura et al, 1996). Serum-dependent invasional activity of
hepatoma cells is regulated by activated RhoA protein (Yoshioka
et al, 1995). In the present study, rhoC gene expression was signif-
icantly higher in tumour portions than in non-tumour portions of
the pancreas. Furthermore, tumours with lymph node metastasis
and those with perineural invasion exhibited significantly higher
expression of the rhoC gene than those without these manifesta-
tions, irrespective ofhistological grading or differentiation. Levels
of the rhoC mRNA were also significantly higher in metastatic
lesions than in primary pancreatic carcinomas. These suggest that
overexpression ofthe rhoC gene occurs during pancreatic carcino-
genesis and that its overexpression may be associated with the
invasive characteristics of pancreatic cancer. As matched pairs of
primary and metastatic lesions could not be compared in the
present study, it remains to be elucidated whether overexpression
of the rhoC gene is directly associated with metastatic process or
not. In the current study, rho gene expressions were only moder-
ately associated each other. RhoA and RhoC proteins are predomi-
nantly associated with the submembranous actin network and
RhoB is found in association with multivesicular bodies
(Robertson et al, 1995). Although rhoA and rhoC expression
levels are not different in human breast cancer cell lines and
normal mammary epithelial cells, rhoB expressions show a
dramatic variation and are implicated in cell proliferation (de
Cremoux et al, 1994). RhoA has weakly transforming activity in
NIH3T3 cells (Avraham and Weinberg, 1989). The rhoB gene is
an immediate-early response gene forepidermal growth factor and
the v-src oncogene (Jahner and Hunter, 1991). Recently, it has
been suggested that RhoC regulates microfilament organization in
the apical pole of intestinal epithelial cells (Nusrat et al, 1995).
Target proteins for each Rho protein could be different (Watanabe
et al, 1996) and the function in carcinogenesis, if any, may be
different in individual Rho proteins.
The incidence ofK-ras gene mutation in ductal adenocarcinoma
of the pancreas in the present study is similar to other previous
reports (Almoguera et al, 1988; Smit et al, 1988; Hruban et al,
1993). It is reported that oncogenic Ras may cause some aspects of
the malignant phenotype by deregulating the Rho family protein
function (Khosravi-Far and Der, 1994). In the present study, the
expression levels of the rho genes have not been affected by the
mutational status ofthe K-ras gene. The activities of Ras and Rho
family proteins may be coordinately regulated by dual-function
proteins such as mCDC25 and p190 through GTP/GDP cycles
(Khosravi-Far and Der, 1994). Thus, it remains possible that the
Ras mutation status influences the Rho function by upregulating
the level ofthe active GTP-bound form irrespective ofRho protein
amount. In the current study mutational change was not detected in
any ofthe rho genes. Mutational activation ofthe rhoA gene is not
observed in lung, breast, colon and ovarian tumours (Moscow et
al, 1994). Thus, rho genes are unlikely to be activated by mutation
during pancreatic carcinogenesis. However, sequencing of entire
coding regions have to be determined to confirm whether mutation
exists or not in the rho genes. In conclusion, the expression level of
the rho genes in ductal adenocarcinoma of the pancreas is not
affected by K-ras gene mutation and rhoC gene overexpression
may play a role in tumour invasion resulting in poorer prognosis.
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